HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
BIOBOARD - INSIDE INDUSTRY
Biolife Science $5m ASX listing to progress stomach & breast cancer vaccine
Australian shareholders are being given the opportunity to buy into a highly promising biotech with a vaccine that shows significant potential in the fight against stomach (gastric) and breast cancer.

Biolife Science Limited will be acquired by Perth-based Acuvax Limited. The Patersons-managed raising aims to generate up to $5 million for Phase II clinical trials of Biolife’s HER-Vaxx vaccine, which has shown significant success in stimulating the production of lifesaving HER-2 antibodies in late-stage cancer patients.

HER-Vaxx is expected to provide a natural, potentially more potent alternative to Roche’s popular injectable antibody, Herceptin®, which has become one of the world’s best-selling cancer drugs with sales of $US6.4 billion in 2012. Metastatic breast cancer patients in Biolife’s Phase I study developed HER-2 antibodies that produced potent anti-tumour activity, thus inducing an antibody response with similar anti-tumour properties to Roche’s Herceptin® and effectively turning the patient’s body into a “Herceptin® factory”.

An Investigational New Drug (IND) application is expected to be filed with the FDA Q3, 2013 and Biolife has already appointed a leading Swiss vaccine producer Pevion Biotech AG to manufacture the HER-Vaxx vaccine. This will be ready for the commencement of the subsequent Phase II clinical study.

The incoming management team includes seasoned biotechnology executives and company builders Dr. Roger Aston and Mr Paul Hopper as well as a Scientific Advisory Board that includes several of the inventors.

Dr. Aston has held leadership roles with ASX listed companies Peptech, Cambridge Antibody, Clinuvel, pSivida and Mayne Pharma. Mr Hopper is Head of the Life Sciences Desk of US investment bank Cappello Capital Corp and is a director of ASX listed Viralytics and pSivida. Both have extensive experience developing vaccines, undertaking clinical trials and marketing products.

Director elect, Dr. Axel Hoos, will also be joining the Board. Dr. Hoos is Vice President, Oncology R&D with GlaxoSmithKline and brings a wealth of experience in cancer drug development to Biolife.

“This is an exhilarating moment for Biolife, which can now see a new life for itself and for one of the most promising new oncology drugs to emerge in recent times,” Dr. Aston said. “We have no doubt that this represents the most expedient way forward for our shareholders, our technology, and – ultimately – for the thousands of cancer patients that stand to benefit from this highly promising vaccine.”

“Given the comparatively low levels of investment activity in Europe, the opportunity has arisen to progress this ground-breaking vaccine with Australian funds for clinical studies in Europe and possibly also in Australia.”

After undergoing a 200 to 1 share consolidation, Acuvax is seeking to raise up to $5 million through the placement of up to 25 million shares at $0.20 each – giving Biolife an initial market cap of $11.3 million and paving the way for the Phase II trials of HER-Vaxx following approval of an FDA IND application.

Stomach cancer and breast cancer are among the most virulent forms of cancer, killing more than 1.2 million people globally each year. The market for stomach cancer drugs alone is projected to rise to nearly $1.4 billion by 2020 – with nearly 20% of patients suffering from HER-2 positive forms of the disease. Between 25-30% of breast cancers are HER-2 positive.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy